Omeros Corporation
NASDAQ:OMERBiotechnology
+$0.43 today
- Market cap
- $1.08B
- Beta
- 2.53
- P/E (TTM)
- 8.4
- EPS (TTM)
- $1.20
Volume 2.53M
Average 1.55M
OMER Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Omeros CorporationNASDAQ: OMER
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $13.12M fell 45.0% year over year, behind the -39.3% change in trailing-twelve-month research & development. Sequentially, it fell 32.5% from the prior quarter. Over 3 fiscal years it compounded at -10.3% a year.
Context
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -45.0% toward the trailing-twelve-month pace of -39.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 81.3M USD
- Year-over-year change
- -32.0%
- 4-year CAGR
- -9.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 81.3M | -32.0% |
| FY2024 | 2024-12-31 | 119.52M | +4.1% |
| FY2023 | 2023-12-31 | 114.87M | +1.9% |
| FY2022 | 2022-12-31 | 112.72M | -5.1% |
| FY2021 | 2021-12-31 | 118.78M | — |
Research & Development vs competitors
How OMER compares with its peers on the latest reported figures
- OMER's LTM Mar 2026 research & development of $70.57M is the 8th highest of the 11 companies compared; the peer median is $133.57M.
- Its year-over-year change of -39.3% is the lowest of 11, against a peer median of +0.7%.
- Research & development amounts to 713.3% of revenue for OMER, versus a peer median of 241.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $497M | +2.5% | +22.0% | 424.8% | |
| LTM Jun 2026 | $467.76M | -32.9% | +13.3% | — | |
| LTM Jun 2026 | $255.77M | +11.4% | +6.3% | 243.6% | |
| LTM Mar 2026 | $188.07M | +22.3% | +26.8% | — | |
| LTM Mar 2026 | $135.36M | -19.9% | -12.2% | 86.2% | |
| LTM Jun 2026 | $131.77M | +6.1% | -18.7% | 241.4% | |
| LTM Mar 2026 | $128.65M | -23.4% | +15.3% | 55.4% | |
| LTM Mar 2026 | $70.57M | -39.3% | -10.3% | 713.3% | |
| LTM Mar 2026 | $37.44M | +64.5% | +11.3% | — | |
| LTM Mar 2026 | $23.92M | -1.0% | -9.4% | 32.9% | |
| LTM Mar 2026 | $18.13M | -12.8% | -16.7% | 3625.8% | |
| Peer median (excluding OMER) | $133.57M | +0.7% | +8.8% | 241.4% | |
Competitors are the stored peer set for OMER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 1.39M | 0 | 0 | 0 | 0 |
| Gross Profit | (1.39M) | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 118.78M | 112.72M | 114.87M | 119.52M | 81.3M |
| Selling, General & Admin | 53.46M | 50.67M | 49.66M | 49.74M | 41.5M |
| Operating Expenses | 172.23M | 163.39M | 164.53M | 169.26M | 122.8M |
| Depreciation & Amortization | 1.39M | 952K | 920K | 950K | 964K |
| EBITDA | (170.49M) | (158.38M) | (143.16M) | (157M) | (1.83M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (173.62M) | (163.39M) | (164.53M) | (169.26M) | (122.8M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 17.93K | 4.06M | 16.34M | 11.3M | 5.06M |
| Interest Expense | 19.67M | 22.7M | 30.84M | 24.68M | 0 |
| Other Income / Expenses | (17.93M) | (18.64M) | (10.39M) | (13.37M) | 120M |
| Income Before Tax | (191.55M) | (182.03M) | (174.92M) | (182.63M) | (2.8M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 2.01M |
| Net Income | (111.41M) | 47.42M | (117.81M) | (156.82M) | (3.35M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | 3.12 | 0.46 | (1.88) | (2.70) | (0.05) |
| EPS (Diluted) | 3.12 | 0.46 | (1.88) | (2.70) | (0.05) |
| Weighted Avg Shares | 62.34M | 62.74M | 62.74M | 58.17M | 63.51M |
| Weighted Avg Shares (Diluted) | 62.34M | 62.74M | 62.74M | 58.17M | 63.51M |
Omeros Corporation
NASDAQ:OMER
Intrinsic Alpha fair value
Locked
Current Price
$14.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.